Biological Activities of Astaxanthin in the Treatment of Neurodegenerative Diseases

Overview

Journal Neurodegener Dis Manag

Date 2024 Dec 9

PMID 39648516

Authors

Alireza Lotfi

Zahra Abroodi

Mozafar Khazaei

Affiliations

Soon will be listed here.

Abstract

Introduction: Neurodegenerative diseases (NDs) develop with the gradual advancement of neuronal damage and dysfunction in the central nervous system (CNS). These disorders are mostly the outcomes of the improper sedimentation and accumulation of proteins, such as amyloid-β (Aβ), α-synuclein, and prions. Astaxanthin (AST) exists in different types of living organisms and displays antioxidant and anti-inflammatory functions. This review has concentrated on the therapeutic characteristics of AST on NDs.

Methods: Data was collected by searching Scopus, PubMed, and Google Scholar databases. Articles selected for this review reported results on the neuroprotective properties of AST on NDs of studies conducted during the years 2000 to 2024.

Results: AST decreases soluble Aβ levels by stimulating the Aβ degradation enzyme. It also reduces inflammation in the substantia nigra (SN) by decreasing IBA1 expression, thereby lessening microglia activity. This carotenoid reduces demyelination by increasing the survival of oligodendrocytes cells and increasing the number of their progenitor cells. AST has antioxidant, anti-inflammatory, and anti-apoptotic properties and can play a role in the treatment of many NDs.

Conclusion: There is no definitive treatment for some NDs. The use of AST and natural compounds can be an optimal method for preventing and treating NDs with few side effects.

References

Arvanitakis Z, Fleischman D, Arfanakis K, Leurgans S, Barnes L, Bennett D . Association of white matter hyperintensities and gray matter volume with cognition in older individuals without cognitive impairment. Brain Struct Funct. 2015; 221(4):2135-46. PMC: 4592368. DOI: 10.1007/s00429-015-1034-7. View

Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, Mahmoudi J . Amyloid-beta: a crucial factor in Alzheimer's disease. Med Princ Pract. 2014; 24(1):1-10. PMC: 5588216. DOI: 10.1159/000369101. View

Devore E, Grodstein F, van Rooij F, Hofman A, Stampfer M, Witteman J . Dietary antioxidants and long-term risk of dementia. Arch Neurol. 2010; 67(7):819-25. PMC: 2923546. DOI: 10.1001/archneurol.2010.144. View

McKee A, Stern R, Nowinski C, Stein T, Alvarez V, Daneshvar D . The spectrum of disease in chronic traumatic encephalopathy. Brain. 2012; 136(Pt 1):43-64. PMC: 3624697. DOI: 10.1093/brain/aws307. View

Lockwood S, Gross G . Disodium disuccinate astaxanthin (Cardax): antioxidant and antiinflammatory cardioprotection. Cardiovasc Drug Rev. 2005; 23(3):199-216. DOI: 10.1111/j.1527-3466.2005.tb00166.x. View

Russo M, Cocco S, Secondo A, Adornetto A, Bassi A, Nunziata A . Cigarette smoke condensate causes a decrease of the gene expression of Cu-Zn superoxide dismutase, Mn superoxide dismutase, glutathione peroxidase, catalase, and free radical-induced cell injury in SH-SY5Y human neuroblastoma cells. Neurotox Res. 2009; 19(1):49-54. DOI: 10.1007/s12640-009-9138-6. View

Kim Y, Koh H, Kim D . Down-regulation of IL-6 production by astaxanthin via ERK-, MSK-, and NF-κB-mediated signals in activated microglia. Int Immunopharmacol. 2010; 10(12):1560-72. DOI: 10.1016/j.intimp.2010.09.007. View

Dugger B, Dickson D . Pathology of Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2017; 9(7). PMC: 5495060. DOI: 10.1101/cshperspect.a028035. View

Lee D, Kim C, Lee Y . Astaxanthin protects against MPTP/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro. Food Chem Toxicol. 2010; 49(1):271-80. PMC: 3010303. DOI: 10.1016/j.fct.2010.10.029. View

10.

Binatti E, Zoccatelli G, Zanoni F, Dona G, Mainente F, Chignola R . Phagocytosis of Astaxanthin-Loaded Microparticles Modulates TGF Production and Intracellular ROS Levels in J774A.1 Macrophages. Mar Drugs. 2021; 19(3). PMC: 8003388. DOI: 10.3390/md19030163. View

11.

Kuroda S, Siesjo B . Reperfusion damage following focal ischemia: pathophysiology and therapeutic windows. Clin Neurosci. 1997; 4(4):199-212. View

12.

Tripathi D, Jena G . Intervention of astaxanthin against cyclophosphamide-induced oxidative stress and DNA damage: a study in mice. Chem Biol Interact. 2009; 180(3):398-406. DOI: 10.1016/j.cbi.2009.03.017. View

13.

Grimmig B, Kim S, Nash K, Bickford P, Shytle R . Neuroprotective mechanisms of astaxanthin: a potential therapeutic role in preserving cognitive function in age and neurodegeneration. Geroscience. 2017; 39(1):19-32. PMC: 5352583. DOI: 10.1007/s11357-017-9958-x. View

14.

Xue Y, Qu Z, Fu J, Zhen J, Wang W, Cai Y . The protective effect of astaxanthin on learning and memory deficits and oxidative stress in a mouse model of repeated cerebral ischemia/reperfusion. Brain Res Bull. 2017; 131:221-228. DOI: 10.1016/j.brainresbull.2017.04.019. View

15.

Shehata M, Ismail A, Kamel M . Combined Donepezil with Astaxanthin via Nanostructured Lipid Carriers Effective Delivery to Brain for Alzheimer's Disease in Rat Model. Int J Nanomedicine. 2023; 18:4193-4227. PMC: 10391537. DOI: 10.2147/IJN.S417928. View

16.

Ghasemi N . The Evaluation of Astaxanthin Effects on Differentiation of Human Adipose Derived Stem Cells into Oligodendrocyte Precursor Cells. Avicenna J Med Biotechnol. 2018; 10(2):69-74. PMC: 5960062. View

17.

Hanzel C, Pichet-Binette A, Pimentel L, Iulita M, Allard S, Ducatenzeiler A . Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiol Aging. 2014; 35(10):2249-62. DOI: 10.1016/j.neurobiolaging.2014.03.026. View

18.

McCarty M, Lerner A . Nutraceutical induction and mimicry of heme oxygenase activity as a strategy for controlling excitotoxicity in brain trauma and ischemic stroke: focus on oxidative stress. Expert Rev Neurother. 2020; 21(2):157-168. DOI: 10.1080/14737175.2021.1861940. View

19.

Nelson S, Varelas P . Status Epilepticus, Refractory Status Epilepticus, and Super-refractory Status Epilepticus. Continuum (Minneap Minn). 2018; 24(6):1683-1707. DOI: 10.1212/CON.0000000000000668. View

20.

Valko K, Ciesla L . Amyotrophic lateral sclerosis. Prog Med Chem. 2019; 58:63-117. DOI: 10.1016/bs.pmch.2018.12.001. View